Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)
2.810
0.00 (0.00%)
At close: Mar 6, 2026
SHE:000518 Revenue
Jiangsu Sihuan Bioengineering had revenue of 112.48M CNY in the quarter ending September 30, 2025, with 124.12% growth. This brings the company's revenue in the last twelve months to 341.90M, up 61.67% year-over-year. In the year 2024, Jiangsu Sihuan Bioengineering had annual revenue of 203.52M, down -13.55%.
Revenue (ttm)
341.90M
Revenue Growth
+61.67%
P/S Ratio
8.46
Revenue / Employee
1.23M
Employees
277
Market Cap
2.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.52M | -31.90M | -13.55% |
| Dec 31, 2023 | 235.42M | -34.73M | -12.86% |
| Jan 1, 2023 | 270.15M | -80.81M | -23.03% |
| Jan 1, 2022 | 350.96M | -154.44M | -30.56% |
| Dec 31, 2020 | 505.40M | 87.52M | 20.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Zhejiang East Asia Pharmaceutical | 831.56M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Cabio Biotech (Wuhan) | 574.88M |
| Suzhou Fushilai Pharmaceutical | 439.57M |
| Shanghai Model Organisms Center | 421.26M |
| Shanghai Hile Bio-Technology | 246.35M |